Technical Data
A2295-28D
ANXA3 (Annexin A3, Annexin-3, Annexin III, Lipocortin III, Placental Anticoagulant Protein III, PAP-III, 35-alpha Calcimedin, Inositol 1,2-cyclic Phosphate 2-phosphohydrolase, ANX3)
|
Technical Data |
|
A2295-28D |
ANXA3 (Annexin A3, Annexin-3, Annexin III, Lipocortin III, Placental Anticoagulant Protein III, PAP-III, 35-alpha Calcimedin, Inositol 1,2-cyclic Phosphate 2-phosphohydrolase, ANX3) |
|
|
Description: Annexin A3 (ANXA3), is a 36kD member of the Annexin family of calcium-dependent phospholipid-binding proteins that are preferentially located on the cytosolic face of the plasma membrane. The Annexins consist of a unique amino terminal domain followed by a homologous C-terminal core domain containing calcium-dependent phospholipid-binding sites. The C-terminal domain is comprised of four 60-70aa annexin repeats. Annexin A3 is upregulated in microglia following stroke and in parenchymal hepatocytes in regenerating liver. It can be up-or down-regulated in various carcinomas. Alternate splicing generates an additional isoform with a 30aa deletion near the N-terminus. Human Annexin A3 shares 89-85aa sequence identity with mouse and rat Annexin A3, respectively. Applications: Suitable for use in Western Blot and Immunohistochemistry. Other applications not tested. Recommended Dilution: Western Blot: 0.1ug/ml Immunohistochemistry: 8-25ug/ml Optimal dilutions to be determined by the researcher. Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. |
|
|||||||||||
|
||||||||||||
|
||||||||||||
|
||||||||||||